Education
About Us
Working with TipRanks
Follow Us
CellaVision AB (CLVSF)
OTHER OTC:CLVSF
Earnings Data
Report Date
Apr 24, 2026Before Open (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
0.18Last Year’s EPS
0.19Same Quarter Last Year
Based on 0 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call presents a broadly positive operational and financial picture: solid revenue and organic growth, a strong EBITDA margin above target, record Americas performance, important strategic progress (bone marrow CE Mark, software validation, DI-60 throughput improvements), a healthy cash position and a proposed dividend increase. Offsetting factors include a weak APAC quarter driven by comparables and tender timing, softness in reagents/software mix that pressured Q4 gross margin, FX headwinds, and near-term uncertainty on revenue ramp from new product launches (bone marrow and U.S. methanol-free reagents). Overall these negatives appear manageable against the company’s clear commercial momentum and strategic milestones.Company Guidance
Q4 Revenue and Organic Growth
Net sales for Q4 increased 5.6% to SEK 197 million, corresponding to organic growth of 12.2% after an FX headwind of -6.6%.
Strong EBITDA and Margin Outperformance
EBITDA of SEK 65 million in Q4, representing a 33% EBITDA margin, above the company's 30% target.
Full-Year Revenue and Organic Growth
Full-year 2025 revenue of SEK 759 million, with 9% organic growth for the year and a full-year gross margin of 68%.
Record Performance in Americas
Americas revenue reached an all-time high of SEK 90 million in Q4 with very strong momentum: reported organic growth ~50% (CEO also referenced 58% organic upside), driven particularly by the U.S. integrated network opportunities.
Instrument Sales Growth and Mix
Instrument revenue of SEK 126 million in the quarter, up 8% year-over-year, with recovery momentum in large integrated placements and improved order-to-install timelines (~2–6 months typical).
Regulatory Milestone — Bone Marrow CE Mark
Achieved CE Mark (Class C, IVDR) for the bone marrow aspirate application, enabling commercial launches in Europe starting in 2026 with expected initial revenues in H2 (ambition for Q4).
Software Upgrade Validated and DI-60 Throughput Improvement
Major software upgrade successfully validated at a customer site; new software (7.2) integrated with DI-60 increases throughput and user experience. Upgrade will be provided as part of instrument offering to protect installed base and support future placements.
R&D Investment and Capitalization Progress
Quarterly R&D spend SEK 37 million (19% of sales). Capitalized SEK 15 million in Q4 (about half of R&D spend), with continued strategic investments and capitalization/depreciation phasing as projects move to launch (e.g., bone marrow).
Cash Position, Cash Flow and Low Leverage
Operating cash flow of SEK 51 million in Q4 and total cash flow SEK 30 million for the quarter; year-end cash balance SEK 188 million. Low financing activity and minimal debt.
Dividend Increase Proposed
Board proposes increasing dividend from SEK 2.50 to SEK 2.75 per share, signaling confidence in cash generation and capital allocation.
Hematology Reagents Growth and APAC Momentum (Selective)
Hematology reagent portfolio (majority of reagent revenues) showed ~10% growth in core markets; APAC hematology reagent revenue grew from SEK 1.4 million to SEK 2.0 million year-over-year (more than doubled), indicating early traction in the region for that product line.
Manufacturing and Market Access in China
Integrated system manufacturing in China enables participation in domestic tenders requiring local production/registration, supporting longer-term APAC/China market opportunities.
CLVSF Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
CLVSF Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 05, 2026 | $15.45 | $15.85 | +2.59% |
Nov 06, 2025 | $18.27 | $16.80 | -8.05% |
Jul 18, 2025 | $16.82 | $16.82 | 0.00% |
Apr 29, 2025 | $16.55 | $16.55 | 0.00% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does CellaVision AB (CLVSF) report earnings?
CellaVision AB (CLVSF) is schdueled to report earning on Apr 24, 2026, Before Open (Confirmed).
What is CellaVision AB (CLVSF) earnings time?
CellaVision AB (CLVSF) earnings time is at Apr 24, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CLVSF EPS forecast?
CLVSF EPS forecast for the fiscal quarter 2026 (Q1) is 0.18.